Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.
NCT ID: NCT00790192
Last Updated: 2016-03-17
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
488 participants
INTERVENTIONAL
2008-10-31
2010-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
NCT00615433
A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia
NCT00044044
A Study of Subjects Switched to Lurasidone for the Treatment of Schizophrenia or Schizoaffective Disorder
NCT01143090
Safety and Tolerability Study of Drug to Treat Schizophrenia
NCT00044005
The Bioequivalence Of Two Different Lurasidone Formulations In Patients
NCT01082250
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Lurasidone 80mg
Lurasidone
Lurasidone 80 mg tablets
Lurasidone 160mg
Lurasidone
Lurasidone 4 40 mg tablets
Quetiapine XR
Quetiapine XR
Quetiapine XR 600mg
Placebo
Placebo
Matching Placebo to Lurasidone or Quetiapine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lurasidone
Lurasidone 80 mg tablets
Lurasidone
Lurasidone 4 40 mg tablets
Quetiapine XR
Quetiapine XR 600mg
Placebo
Matching Placebo to Lurasidone or Quetiapine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Meets DSM-IV™ criteria for a primary diagnosis of schizophrenia.
* Not pregnant, if of reproductive potential agrees to remain abstinent or use adequate and reliable contraception for duration of study.
* Able and agrees to remain off prior antipsychotic medication for the duration of study.
* Good physical health on the basis of medical history, physical examination, and laboratory screening.
* Willing and able to comply with the protocol, including the inpatient requirements and outpatient visits.
Exclusion Criteria
* Any chronic organic disease of the CNS (other than schizophrenia).
* Used investigational compound within 30 days.
* Clinically significant or history of alcohol abuse/alcoholism or drug abuse/dependence within the last 6 months.
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sumitomo Pharma America, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Director, MD
Role: STUDY_DIRECTOR
Sumitomo Pharma America, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
K&S Professional Research Services, LLC
Little Rock, Arkansas, United States
Woodland International Research Group
Little Rock, Arkansas, United States
Clinical Pharmacological Studies, Inc.
Cerritos, California, United States
Comprehensive Neuroscience, Inc
Cerritos, California, United States
Clinical Innovations, Inc.
Costa Mesa, California, United States
Synergy Escondido
Escondido, California, United States
Collaborative Neuroscience Network
Garden Grove, California, United States
Apostle Clinical Trials, Inc.
Long Beach, California, United States
California Clinical Trials
Paramount, California, United States
Pasadena Research Institute
Pasadena, California, United States
CNRI-Los Angeles. LLC
Pico Rivera, California, United States
Clinical Innovations, Inc.
Riverside, California, United States
CNRI-San Diego
San Diego, California, United States
UCSD Medical Center
Sandeigo, California, United States
Segal Institute for Clinical Research
Highlands Ranch, Colorado, United States
Comprehensive Neuroscience, Inc.
Washington D.C., District of Columbia, United States
Florida Clinical Research Center
Bradenton, Florida, United States
Florida Clinical Research Center, LLC
Fruitland Park, Florida, United States
Lake Charles Clinical Trials
Lake Charles, Louisiana, United States
Booker, J. Gary, MD. APMC
Shreveport, Louisiana, United States
Precise Clinical Research
Flowood, Mississippi, United States
St. Charles Psychiatric Associates
Saint Charles, Missouri, United States
St. Louis Research, Inc.
St Louis, Missouri, United States
CRI Worldwide
Willingboro, New Jersey, United States
Comprehensive Neuroscience, Inc
Holliswood, New York, United States
Segal Institute for Clinical Research
Winston-Salem, North Carolina, United States
Community Clinical Research
Austin, Texas, United States
Future Search Trials of Neurology
Austin, Texas, United States
Pillar Clinical Research
Dallas, Texas, United States
S.V. Medical College
Tirupati, Andhra Pradesh, India
Vijayawada Institute of Mental Health and Neurosciences
Vijayawada, Andhra Pradesh, India
Seth K M School of P G Medicine & Research
Ahmedabad, Gujarat, India
SBKS Medical Institute and Research Centre
Vadodara, Gujarat, India
Justice K.S. Hegde Charitable Hospital
Mangalore, Karnataka, India
JSS Medical College and Hospital
Mysore, Karnataka, India
Shanti Nursing Home
Aurangabad, Maharashtra, India
Deenanath Mangeshkar Hospital and Research Centre
Pune, Maharashtra, India
Mahatma Gandhi Institute of Medical Sciences
Sewāgrām, Maharashtra, India
Madras Medical College & Government General Hospital
Chennai, Tamil Nadu, India
Spitalul Clinic Judetean de Urgenta Arad
Str. Octavian Goga Nr. 17, Arad, Romania
Spitalul de Psihiatrie Titan "Dr. Constantin Gorgos"
Bdul Nicolae Grigorescu Nr. 41, București, Romania
Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
Sos. Berceni Nr. 10-12, București, Romania
Spitalul Judetean Arges
Str. Negru Voda Nr. 53, Pitesti, Romania
Spitalul Clinic de Psihiatrie Prof. Dr. Alexandru Obregia
Bucharest, , Romania
Spitalul Clinic de Neurologie si Psihiatrie Oradea
Oradea, , Romania
SEI of H.P. Educat. Northern SMU
Arkhangelsk, , Russia
St. Petersburg SHI Psychiatrical Hosptial #1 n.a. Kaschenko
Gatchina, , Russia
Moscow Scientific Research Institute of Psychiatry
Moscow, , Russia
Institution of RAMS Mental Health Research Center of RAMS
Moscow, , Russia
City Clinical Psichiatric Hospital #1
Nizhny Novgorod, , Russia
City Psychiatric Hospital #2 of St. Nikolay Chudotvorets
Saint Petersburg, , Russia
City Psychiatric Hospital #3 of Skvortsov-Stepanov
Saint Petersburg, , Russia
City Psychiatric Hospital #4
Saint Petersburg, , Russia
SHI City Psychoneurological Dispensary #7
Saint Petersburg, , Russia
St. Petersburg GUZ City Psychiatric Hospital #6
Saint Petersburg, , Russia
SHI Samara Psychiatric Hospital
Samara, , Russia
Kherson Regional Psychiatric Hospital
Kherson,vil., Stepanovka, Ukraine
RCH n.a.I.I.Mechnikov, Reg.Cent. of Psychosom. Pathology
Dnipropetrovsk, , Ukraine
Chair of Psychiatry and Medical Psychology
Donetsk, , Ukraine
Centre of Novel Treatment and Rehabilitation of Psychotic disorders
Kyiv, , Ukraine
Kyiv City Psychoneurological Hospital
Kyviv, , Ukraine
Lviv Reg.St.Cl.Psych.Hosp
Lviv, , Ukraine
Reg. Psychiatric Hospital
Odesa, , Ukraine
Poltava Regional Clinical Psychiatric Hospital,
Poltava, , Ukraine
Crimean republican Clinical Psychiatric Hospital
Simferopol, , Ukraine
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Loebel A, Cucchiaro J, Sarma K, Xu L, Hsu C, Kalali AH, Pikalov A, Potkin SG. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res. 2013 Apr;145(1-3):101-9. doi: 10.1016/j.schres.2013.01.009. Epub 2013 Feb 13.
Harvey PD, Siu CO, Hsu J, Cucchiaro J, Maruff P, Loebel A. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: a short-term placebo- and active-controlled study followed by a 6-month double-blind extension. Eur Neuropsychopharmacol. 2013 Nov;23(11):1373-82. doi: 10.1016/j.euroneuro.2013.08.003. Epub 2013 Aug 27.
Loebel AD, Siu CO, Cucchiaro JB, Pikalov AA, Harvey PD. Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia. CNS Spectr. 2014 Apr;19(2):197-205. doi: 10.1017/S1092852913000904. Epub 2013 Dec 13.
Hopkins SC, Tomioka S, Ogirala A, Loebel A, Koblan KS, Marder SR. Assessment of Negative Symptoms in Clinical Trials of Acute Schizophrenia: Test of a Novel Enrichment Strategy. Schizophr Bull Open. 2022 Apr 7;3(1):sgac027. doi: 10.1093/schizbullopen/sgac027. eCollection 2022 Jan.
Hopkins SC, Ogirala A, Worden M, Koblan KS. Depicting Safety Profile of TAAR1 Agonist Ulotaront Relative to Reactions Anticipated for a Dopamine D2-Based Pharmacological Class in FAERS. Clin Drug Investig. 2021 Dec;41(12):1067-1073. doi: 10.1007/s40261-021-01094-7. Epub 2021 Nov 9.
Harvey PD, Siu CO, Ogasa M, Loebel A. Effect of lurasidone dose on cognition in patients with schizophrenia: post-hoc analysis of a long-term, double-blind continuation study. Schizophr Res. 2015 Aug;166(1-3):334-8. doi: 10.1016/j.schres.2015.06.008. Epub 2015 Jun 24.
Nasrallah HA, Cucchiaro JB, Mao Y, Pikalov AA, Loebel AD. Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr. 2015 Apr;20(2):140-7. doi: 10.1017/S1092852914000285. Epub 2014 Jun 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
D1050233
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.